CytoMed Therapeutics Limited (GDTC:NASDAQ) closed at $0.829 on November 13, 2026, down 1.74% on the day. The stock trades 63.8% below its 52-week high of $2.29 and 22.0% above its 52-week low of $0.680. Over the past year, it lost 58.1%. CytoMed Therapeutics Limited is part of the Health Care sector.
In 252 trading sessions since November 13, 2025, GDTC closed higher on 98 days (39%). Its best day was May 15, 2026 (+31.82%) and its worst was January 14, 2026 (-23.36%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 6 times.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors.
Find more stocks like GDTC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.